Archive for category: E-News

E-News

Messe Düsseldorf Group to organize new MEDICAL FAIR BRASIL

, /in /by

The Messe Düsseldorf Group is re-focusing their activities on the health market in Brazil and will organize the first MEDICAL FAIR BRASIL from May 5 – 8, 2020 at  the Expo Center Norte in Sao Paulo. It will be an annual event. MEDICAL FAIR BRASIL is supported by and staged in cooperation with the Brazilian medical technology manufacturers association ABIMO. Messe Düsseldorf’s foreign representation in Brazil is responsible for organizing the event.
 “With Messe Düsseldorf and ABIMO, two strong partners are working on the mutual goal of establishing MEDICAL FAIR BRASIL as Brazil’s leading event platform. Using our global network of 75 foreign representations and 12 affiliated companies or subsidiaries, we promote the event in over 130 countries and contribute our valuable experience in organizing medical trade fairs,” explained Wolfram Diener, Managing Director of Messe Düsseldorf. 
The Messe Düsseldorf Group has been organizing successful healthcare events around the globe for many years. In 2017, these healthcare events were grouped under the new umbrella brand “MEDICAlliance” in order to be marketed as a unit worldwide. In addition to the world-leading trade fair MEDICA and the internationally leading supplier trade fair COMPAMED (held concurrently in Düsseldorf, Germany) , the alliance includes MEDICAL FAIR INDIA (Mumbai/New Delhi), MEDICAL FAIR ASIA (Singapore), MEDICAL FAIR THAILAND (Bangkok) and MEDICAL FAIR CHINA (Suzhou).  
For the South American market, MEDICAL FAIR BRASIL is now being added as a further member of MEDICAlliance. Meditech in Colombia (Bogota) already successfully represents MEDICAlliance in South America. 
 “We know the market and are already well connected in the industry in Brazil thanks to our previous commitments. For us, it is strategically important to have a strong presence on this market with MEDICAlliance. Positive growth prospects and Brazilian business partners, who in our experience are reliable and sincere, are the ideal foundation on which to build a top business,” said Horst Giesen, Global Portfolio Director Health & Medical Technologies at Messe Düsseldorf. The Brazilian market’s volume for medical technology is approximately $ 5.7 billion (source: gtai) and the healthcare industry is among the industries with the highest growth rates in the country.
Paulo Fraccaro, Superintendent at ABIMO, is also looking forward to the cooperation for MEDICAL FAIR BRASIL: “The cooperation between ABIMO and Messe Düsseldorf will bring forth a strong alliance. Together, we are creating the ideal platform for companies to present their innovations and meet relevant decision-makers – both those active in health care as well as manufacturers and distributors in other countries.”
Key exhibit categories at MEDICAL FAIR BRASIL are: Medical technology / medical products, laboratory technology and diagnostics, health IT, physiotherapy and orthopedic technology as well as medical services. The trade fair primarily addresses physicians, medical professionals and managers of health institutions as well as health industry service suppliers and experts in the fields of science, politics, trade and industry.
 
http://www.medicalfair-brasil.com
www.mdna.com
http://abimo.org.br

International Hospital Federation Awards deadline extended to 3rd June

, /in /by

Due to overwhelming demand, entry submissions for the 2019 International Hospital Federation (IHF) Awards has just been extended to 3rd June. Hospitals and health service providers can still nominate their outstanding and innovative projects and programs.
The IHF Awards Committee announced that the extension of the deadline of entries is to give more organizations an opportunity to nominate exemplary programs that deserve international recognition.
There are four categories in total:
1. IHF/Dr Kwang Tae Kim Grand Award
2. IHF/Bionexo Excellence Award for Corporate Social Responsibility
3. IHF/EOH Excellence Award for Leadership and Management in Healthcare
4. IHF/Austco Excellence Award for Quality & Safety and Patient-centered Care
The Awards is open to all public and private healthcare provider organizations. The submission process is simple and at no cost. Interested organizations only need to create an account in the IHF Awards website to accomplish the entry form.
Winners will be awarded in front of industry peers at the Awards Ceremony during the 43rd IHF World Hospital Congress in Muscat, Oman in November.
The 2019 International Hospital Federation (IHF) Awards is sponsored by Dr Kwang Tae Kim, Austco, Bionexo, and EOH. https://congress.ihf-fih.org/ihf_awards

‘Questions from the frontline’ — initiative answers clinicians Covid-19 pathophysiology questions

, /in , /by

Frontline clinicians treating coronavirus patients can now gain access to the latest advice from a panel of human physiology experts. Frontline medics can ask anything about how the body might function in response to the disease.
The aim is to provide clinicians with an evolving understanding of the physiological and pathophysiological mechanisms that both underpin this disease and determine its outcome and mitigation.
The initiative is a joint venture between The Physiological Society and the Intensive Care Society, which is being co-ordinated by Mike Tipton, Professor of Human and Applied Physiology at the University of Portsmouth and David Paterson, Professor of Cardiovascular Physiology at the University of Oxford,.
Questions, comments and data from frontline clinicians dealing with patients are responded to by a Covid-19 advisory panel consisting of 24 specialists with diverse physiological expertise.
Professor Tipton said: “Following a discussion with Hugh Montgomery, a professor of intensive care medicine, it was clear that our clinical colleagues were working flat out whilst most of our academic colleagues were not able to deploy their expertise, sitting at home isolating.
Anyone can access the website to read the questions and responses, but only clinicians can register to ask questions or comment.
Questions from the frontline: https://www.physoc.org/covid19/questions

Sanofi and GSK partner to develop vaccine against COVID-19

, /in , /by

Sanofi and GSK will partner to develop an adjuvanted vaccine for COVID-19, using technology from both companies.
Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology. This technology has produced an exact genetic match to proteins found on the surface of the virus, and the DNA sequence encoding this antigen has been combined into the DNA of the baculovirus expression platform, the basis of Sanofi’s licensed recombinant influenza product in the US.
GSK will contribute its proven pandemic adjuvant technology. The use of an adjuvant can be of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protect more people.
The companies plan to initiate phase I clinical trials in the second half of 2020 and, if successful, subject to regulatory considerations, aim to complete the development required for availability by the second half of 2021.
Paul Hudson, Chief Executive Officer, Sanofi, commented: “As the world faces this unprecedented global health crisis, it is clear that no one company can go it alone. That is why Sanofi is continuing to complement its expertise and resources with our peers, such as GSK, with the goal to create and supply sufficient quantities of vaccines that will help stop this virus.”
Emma Walmsley, Chief Executive Officer, GSK, said: “This collaboration brings together two of the world’s largest vaccines companies. By combining our scientific expertise, technologies and capabilities, we believe that we can help accelerate the global effort to develop a vaccine to protect as many people as possible from COVID-19.”
The combination of a protein-based antigen together with an adjuvant is well-established and used in a number of vaccines available today. An adjuvant is added to some vaccines to enhance the immune response and has been shown to create a stronger and longer- lasting immunity against infections than the vaccine alone. It can also improve the likelihood of delivering an effective vaccine that can be manufactured at scale.
The combination of a protein-based antigen together with an adjuvant is well-established and used in a number of vaccines available today. An adjuvant is added to some vaccines to enhance the immune response and has been shown to create a stronger and longer- lasting immunity against infections than the vaccine alone. It can also improve the likelihood of delivering an effective vaccine that can be manufactured at scale.
Rick A. Bright, Ph.D., BARDA Director, said: “Strategic alliances among vaccine industry leaders are essential to make a coronavirus vaccine available as soon as possible. Development of the adjuvanted recombinant-based COVID-19 vaccine candidate holds the potential to lower the vaccine dose to provide vaccine to a greater number of people to end this pandemic, and help the world become better prepared or even prevent future coronavirus outbreaks.”
The companies have set up a Joint Task Force, co-chaired by David Loew, Global Head of Vaccines, Sanofi and Roger Connor, President Vaccines, GSK. The taskforce will seek to mobilize resources from both companies to look for every opportunity to accelerate the development of the candidate vaccine.

Astell Scientific at Medica

, /in /by

Astell Scientific is a world renowned manufacturer and supplier of steam sterilizers. Astell Scientific autoclaves, steam generators and effluent decontamination systems (EDS) are designed to meet the exacting demands of modern Laboratory, Research and Medical professionals, and as such incorporate innovations such as colour touchscreen controllers as standard throughout the range.

We manufacture:
•    Circular section autoclaves from 30-330 litres
•    Square Section autoclaves from 125 – 2000 litres
•    Steam Generators up to 72 kW
•    Effluent Decontamination Systems (EDS)
•    Customized steam sterilizers to meet the most challenging of applications
All Astell autoclaves are manufactured in accordance with standards and directives including ISO 9001:2015, Pressure Equipment Directive (PED 2014/68/EU) and CE (Conformité Européenne).www.astell.comBooth # 1G11-1

Near-simultaneous admissions may affect mortality and length of stay in the ICU

, /in /by

A strain in ICU capacity has been linked to adverse patient outcomes. New research suggests that near-simultaneous ICU admissions are frequent and may also have an adverse effect on patient outcomes. Researchers conducted an observational study of patients admitted to an academic adult ICU of a tertiary medical centre. Over the five-year period of the study, they found a correlation between the elapsed time between two consecutive admissions and mortality.
Researchers examined 13,234 consecutive ICU admissions. A quarter of these admissions had an elapsed time between two consecutive admissions of less than 55 minutes. They found a “dose-dependent” and inverse relationship between the elapsed time between admissions and mortality. In summary, the shorter the interval between admissions, the higher the odds of death. Specifically, the adjusted odds ratio (OR) of death gradually decreased by an additional average of 0.93 (95% CI 0.9‒0.97, P=.001) for each log(unit) of time separating admissions.
“This study shows that providing the same level of care during multiple admissions is difficult when patients of equal severity arrive at the same time. Further studies are needed to confirm these findings and work towards ways to improve mechanisms, structures and processes to improve patient outcomes regardless of admission rates,” says Dr. Markos Kashiouris, lead researcher.
CHESThttps://tinyurl.com/y46pl9lf

Removing more blood via minimally invasive surgery more likely to improve haemorrhagic stroke recovery

, /in /by

The greater the volume of blood removed from the brain via minimally invasive surgery after a cerebral haemorrhage the greater the odds of better functional recovery, according to late breaking science presented at the American Stroke Association’s International Stroke Conference 2019.
Minimally Invasive Surgery Plus Alteplase for Intra-cerebral Haemorrhage Evacuation (MISTIE) is the stereotactic catheter aspiration and clearance of large bleeds within the brain, with the clot-buster alteplase.
The MISTIE III trial is the first surgical trial assessment of whether greater removal of blood impacts the likelihood of favourable functional outcome after one year and factors associated with greater efficiency of blood removal.
Among 506 intra-cerebral haemorrhage (ICH) cases enrolled in the trial, 242 ICH patients (average age 62, 63 percent male) underwent the MISTIE III surgical procedure by 110 surgeons at 73 sites, with follow-up at one year. The trial excluded patients whose bleeding had not stabilized, and cases with cerebellar and brainstem haemorrhage.
Researchers found that among cases undergoing the MISTIE III surgical procedure, removing blood volume by 70 percent or more, or leaving 15 milliliters or less of residual blood at the end of treatment were twice as likely to achieve milder disability one year later. Lesser removal was needed to avoid mortality, but the patients who had less than 70 percent of the blood removed, or more than 15 mL residual blood, had no difference in disability than patients treated with medical therapy, or those with lesser removal.
Researchers noted that more efficient ICH evacuation was more likely accomplished in cases with certain shapes of hematoma, where the surgical protocol was rigorously followed and by surgeons and sites with greatest experience in MISTIE technique.
“When assessing the results of surgery for brain haemorrhage, it is critical to consider how much blood was successfully evacuated. Unless a large majority of clot is removed and only a very small residual of blood is left, the full benefits of surgery will not be realized,” said Issam A. Awad, M.D, M.Sc., study lead author and director of Neurovascular Surgery at the University of Chicago Medicine and Biological Sciences. “This had never been considered as a factor in the success or failure of such surgeries and cannot be taken for granted.”
American Heart Association https://tinyurl.com/y2n7kt35

Antibiotic side effects in kids lead to nearly 70,000 ER visits in the U.S. each year

, /in /by

The use of antibiotics drives the development of antibiotic resistance, a major threat to public health worldwide. But these drugs also carry the risk of harm to individual patients, including children. According to a new analysis antibiotics led to nearly 70,000 estimated emergency room visits in the U.S. each year from 2011-2015 for allergic reactions and other side effects in children. The study helps quantify the risk posed by specific antibiotics in children across different age ranges.
“For parents and other caregivers of children, these findings are a reminder that while antibiotics save lives when used appropriately, antibiotics also can harm children and should only be used when needed,” said lead author Maribeth C. Lovegrove, MPH, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention. “For healthcare providers, these findings are a reminder that adverse effects from antibiotics are common and can be clinically significant and consequential for pediatric patients.”
For their analysis, researchers used nationwide estimates for outpatient antibiotic prescriptions and data from a nationally representative sample of hospitals for emergency room visits attributed to the use of antibiotics by children aged 19 and younger. Most of the visits (86 percent) were for allergic reactions, such as a rash, pruritus (itching), or angioedema (severe swelling beneath the skin). The risk of a visit varied by child age and type of antibiotic, but for most antibiotics, children aged 2 or younger had the highest risk of an adverse drug event. Forty-one percent of visits involved children in this age group. Amoxicillin was the most commonly implicated antibiotic in adverse drug events among children aged 9 or younger, while sulfamethoxazole/trimethoprim was most commonly implicated among children 10-19 years old.
Antibiotics are among the most commonly prescribed medications for children, but prior research has suggested that nearly a third, if not more, of outpatient pediatric prescriptions for antibiotics are unnecessary. Efforts to reduce antibiotic overprescribing have largely focused on reducing antibiotic resistance. However, studies have shown that these longer-term societal risks are not always prioritized when clinicians are making decisions about treatment.
“By considering available data on the immediate risks to individual patients, clinicians, and parents and caregivers, can better weigh the risks and benefits of antibiotic treatment,” Lovegrove said.
The researchers were not able to determine which antibiotic prescriptions were unnecessary or inappropriate in the study, because data for antibiotic indications, doses, and durations of therapy were not available. The study also likely underestimates how often children experience adverse side effects from antibiotics because the analysis includes only adverse drug events that resulted in a visit to an emergency room. Adverse drug events treated in other settings, such as an urgent care facility or a doctor’s office, or cases for which no healthcare was sought, were not included. Also, adverse events that are less likely to be diagnosed in the emergency room setting (e.g., Clostridium difficile infections that can cause severe diarrhea after antibiotic use) were not included.
Pediatric Infectious Disease Society https://tinyurl.com/yctsaxrn

Oxford COVID-19 policy ‘Supertracker’ wins support from OECD, World Bank

, /in , /by

Oxford has launched the ‘Oxford Supertracker’ < https://supertracker.spi.ox.ac.uk > – a global directory for COVID-19 policy trackers and surveys – to enable policy-makers and stakeholders to follow and evaluate policy changes and their impact on the COVID-19 pandemic in the UK, Europe and around the world.
Marek Naczyk, Oxford Associate Professor in Comparative Social Policy and project lead, said: “As social scientists and concerned citizens, we felt compelled to work on this tool to ensure policy-makers and the public can access information on policy measures in the wake of COVID-19. We have been encouraged by the interest to date from many international organisations, including OECD and the World Bank, highlighting how the Department of Social Policy’s interdisciplinary background is well placed for the continued development of the tool. Our ambition is for the Oxford ‘Supertracker’ to be the go-to portal sharing all known policy-related data sources in one place.”
Numerous organisations have produced trackers to allow policy-makers and stakeholders to follow and evaluate policy changes and their impact on the pandemic. The Oxford Supertracker project makes this information freely available with one tool, allowing users to search and identify international policy.
Sebastian Königs and Andrea Garnero, Economists at The Organisation for Economic Co-operation and Development (OECD) said: “The team behind the Oxford Supertracker have done an impressive job in assembling the rapidly growing data on countries’ COVID responses and in making them readily available and easily searchable. This is an enormous service to the research and policy community, including many here at the OECD.”
Ugo Gentilini, Global Lead for Social Assistance at the World Bank, commented on the Supertracker, saying: “The Oxford Supertracker offers a precious compass to help policy-makers, practitioners and researchers to navigate the rich and evolving set of trackers available globally.”
The COVID-19 policy tracker started in March as a Twitter thread by Oxford DPhil student Lukas Lehner. But it has evolved into the Supertracker, a comprehensive global directory of more than 100 data sources.
Compiling policy trackers and surveys, the Supertracker allows users to search by:

  • Policy area – such as ‘education’ or ‘social and economic’
  • Country coverage
  • Data format, and
  • Author.

It will be updated with input from policy-makers, researchers and users, to identify symmetries and gaps in existing trackers and propose concrete actions to address these. These will be particularly relevant to the social policy and economic inequality prevention measures, that are put in place as lockdown policies ease.
Visit the Oxford Supertracker here: https://supertracker.spi.ox.ac.uk A data summary can be downloaded as a CSV for offline analysis.

Coronavirus Global Response raises €7.4 billion in pledges

, /in /by

€7.4 billion was raised at the Coronavirus Global Response pledging event on 4 May to kick-start an unprecedented global cooperation between scientists and regulators, industry and governments, international organisations, foundations and health care professionals to ensure the collaborative development and universal deployment of diagnostics, treatments and vaccines against coronavirus.
The pledging event was co-convened by the European Union, Canada, France, Germany, Italy, Japan, the Kingdom of Saudi Arabia, Norway, Spain and the United Kingdom. It builds on the commitment made by G20 leaders on 26 March and follows a call by the WHO on 24 April for a global collaboration for the accelerated development, production and equitable global access to new coronavirus essential health technologies.
Commenting on the success of the event, President of the European Commission, Ursula von der Leyen, said: “The world showed extraordinary unity for the common good. Governments and global health organisations joined forces against coronavirus. With such commitment, we are on track for developing, producing and deploying a vaccine for all. However, this is only the beginning. We need to sustain the effort and to stand ready to contribute more. The pledging marathon will continue. After governments, civil society and people worldwide need to join in, in a global mobilisation of hope and resolve.”
The funds raised will be channelled primarily through recognised global health organisations such as CEPI, Gavi, the Vaccines Alliance, as well as the Global Fund and Unitaid into developing and deploying as quickly as possible, for as many as possible, the diagnostics, treatments and vaccines that will help the world overcome the pandemic.
The Coronavirus Global Response Initiative is comprised of three partnerships for testing, treating and preventing underpinned by health systems strengthening. The three partnerships will work as autonomously as possible, with a transversal work stream on enhancing the capacity of health systems and knowledge and data sharing.
The European Commission will register and keep track of pledges up until end of May but will not receive any payments into its accounts. Funds go directly to the recipients. Recipients will, however, not decide alone on the use of the donation, but deploy it in concert with the partnership. The commitment is for all new vaccines, diagnostics and treatments against coronavirus to be made available globally for an affordable price, regardless of where they were developed.
The Global Vaccines Summit that Gavi, the Vaccine Alliance, will organise on 4 June will mobilise additional funding to protect the next generation with vaccines. As the world relies on Gavi’s work for making vaccination available everywhere, the success of Gavi’s replenishment will be crucial to the success of the Coronavirus Global Response.
In an Op-ed ahead of the pledging event, co-authored by Giuseppe Conte, President of the Government of the Italian Republic, Emmanuel Macron, President of the French Republic, Angela Merkel, Federal Chancellor of the Federal Republic of Germany, Charles Michel, President of the European Council, Erna Solberg, Prime Minister of the Kingdom of Norway, Justin Trudeau, Prime Minister of Canada and Ursula von der Leyen, President of the European Commission, they said: “None of us is immune to the pandemic and none of us can beat the virus alone. In fact, we will not truly be safe until all of us are safe – across every village, city, region and country in the world. In our interconnected world, the global health system is as strong as its weakest part. We will need to protect each other to protect ourselves.
“This poses a unique and truly global challenge. And it makes it imperative that we give ourselves the best chance to defeat it. This means bringing together the world’s best – and most prepared – minds to find the vaccines, treatments and therapies we need to make our world healthy again
“This is our generation’s duty and we know we can make this happen. High quality and low-cost health technologies are not a daydream. And we have seen how public-private partnerships have managed to make many life-saving vaccines available to the poorest people on earth over the last two decades.
“This is a defining moment for the global community. By rallying around science and solidarity today we will sow the seeds for greater unity tomorrow. Guided by the Sustainable Development Goals, we can redesign the power of community, society and global collaboration, to make sure that nobody is left behind.”
Coronavirus Global Response https://global-response.europa.eu

Latest issue of International Hospital

April 2024

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The medical devices information portal connecting healthcare professionals to global vendors

Sign in for our newsletter

Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@interhospi.com

PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.